Palbociclib/palbociclib: Representative of a new generation of targeted drugs

Palbociclib/ Palbociclib, also known as Ibrance, is a revolutionary cancer-targeted drug. As a third-generation cyclin-dependent kinase inhibitor (CDKis), it has demonstrated outstanding performance in the treatment of advanced and metastatic breast cancer, marking a new chapter in this established treatment class.

Althoughthe therapeutic effects of CDKis vary among individuals, and some patients may experience toxic reactions or other unexpected situations, palbociclib stands out for its excellent safety and tolerability. It is particularly suitable for patients with hormone receptor-positive, HER2-negative advanced breast cancer and has become an important treatment option for such patients.

Doctors may recommend palbociclib treatment when breast cancer has spread to the area around the breast, such as nearby lymph nodes, muscles, and skin, or even to other parts of the body. The drug's therapeutic strategy targets estrogen receptor-positive (ER+) and human epidermal growth factor receptor-negative (HER2-) breast cancers.

In order to enhance the efficacy, palbociclib is often used in combination with drugs such as aromatase inhibitors or fulvestrant (Fulvestrant). Its unique mechanism of action lies in its ability to target cyclin-dependent kinases 4 and 6 (CDK 4 and CDK6) on cancer cells. These proteins are key factors in stimulating the growth and division of cancer cells. By blocking the function of these proteins, palbociclib aims to slow or stop the progression of cancer.

However, it should be emphasized that palbociclib is not suitable for all breast cancer patients and may be associated with side effects such as low blood cell counts, fatigue, and nausea. Therefore, doctors will conduct comprehensive assessment and guidance before starting treatment, and conduct regular monitoring during the treatment process to ensure patient safety and treatment effectiveness.